The Great Healthcare Debate 7 DAYS · Free panel + drinks · 12 May · London RSVP free →

European and London Stock Market

16 June 1996

EUROPEAN: bourses were divergent in their movement. In PARIS, share prices remained in quite a tight range until employment data was released in the USA. Interest rate cuts in France and the UK did produce some gains but theses were wiped out when the employment news from the USA proved disappointing to the optimists. The CAC 40 index fell back to close the reporting period unchanged. Chemical and pharmaceutical stock Rhone-Poulenc, in a move to reduce its debt, announced that its health care business Rhone-Poulenc Rorer had agreed to sell its Fisons Rochester, USA, facility to the UK company Medeva (Marketletter June 10). The news pleased the market and R-P's share price rose. In FRANKFURT, share prices declined. Andrew Fisher, writing in the Financial Times, noted that after an impressive burst at the beginning of the year, the German stock market has stopped in its tracks. Some analysts believe that a correction may be around the corner and investors are being advised to hold back from purchasing new shares. With a weak German economy, economists are divided as to how quickly and how soon it will recover. Mr Fisher pointed out that one area of change is in the corporate arena, where companies are altering the way they treat shareholders and organise their activities. An example is Hoechst, which is undergoing intensive restructuring (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight